vs
Side-by-side financial comparison of MARA Holdings, Inc. (MARA) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
MARA Holdings, Inc. is the larger business by last-quarter revenue ($202.3M vs $177.4M, roughly 1.1× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -14298.3%, a 14299.9% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -5.6%). Over the past eight quarters, MARA Holdings, Inc.'s revenue compounded faster (10.7% CAGR vs -0.2%).
MARA Holdings, Inc. is an American digital asset technology and cryptocurrency mining company headquartered in Fort Lauderdale, Florida. Founded in 2010, the company initially operated as a patent holding company before pivoting in the late 2010s to focus on blockchain infrastructure and digital assets.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
MARA vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $202.3M | $177.4M |
| Net Profit | $-1.7B | $2.9M |
| Gross Margin | — | — |
| Operating Margin | -11795.9% | 3.9% |
| Net Margin | -14298.3% | 1.6% |
| Revenue YoY | -5.6% | 5.0% |
| Net Profit YoY | -423.5% | — |
| EPS (diluted) | $-4.25 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $202.3M | $196.9M | ||
| Q3 25 | $252.4M | $179.5M | ||
| Q2 25 | $238.5M | $181.1M | ||
| Q1 25 | $213.9M | $168.9M | ||
| Q4 24 | $214.4M | $187.3M | ||
| Q3 24 | $131.6M | $168.6M | ||
| Q2 24 | $145.1M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-1.7B | — | ||
| Q3 25 | $123.1M | $5.4M | ||
| Q2 25 | $808.2M | $-4.8M | ||
| Q1 25 | $-533.4M | $4.8M | ||
| Q4 24 | $528.5M | — | ||
| Q3 24 | $-124.8M | $-143.5M | ||
| Q2 24 | $-199.7M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | -2613.4% | 78.7% | ||
| Q3 24 | -1065.0% | 76.9% | ||
| Q2 24 | -587.6% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -11795.9% | 1.2% | ||
| Q3 25 | 18.9% | 3.5% | ||
| Q2 25 | — | 4.7% | ||
| Q1 25 | -253.0% | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | -130.8% | -82.8% | ||
| Q2 24 | -160.1% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -14298.3% | — | ||
| Q3 25 | 48.8% | 3.0% | ||
| Q2 25 | 338.9% | -2.7% | ||
| Q1 25 | -249.4% | 2.8% | ||
| Q4 24 | 5367.4% | — | ||
| Q3 24 | -94.8% | -85.1% | ||
| Q2 24 | -137.6% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-4.25 | $0.05 | ||
| Q3 25 | $0.27 | $0.12 | ||
| Q2 25 | $1.84 | $-0.11 | ||
| Q1 25 | $-1.55 | $0.10 | ||
| Q4 24 | $1.60 | $0.38 | ||
| Q3 24 | $-0.42 | $-3.11 | ||
| Q2 24 | $-0.72 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $547.1M | $144.3M |
| Total DebtLower is stronger | $3.6B | — |
| Stockholders' EquityBook value | $3.5B | $653.9M |
| Total Assets | $7.3B | $1.2B |
| Debt / EquityLower = less leverage | 1.04× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $547.1M | $238.4M | ||
| Q3 25 | $826.4M | $246.3M | ||
| Q2 25 | $109.5M | $445.9M | ||
| Q1 25 | $196.2M | $493.6M | ||
| Q4 24 | $391.8M | $484.6M | ||
| Q3 24 | $164.3M | $453.8M | ||
| Q2 24 | $256.0M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $3.6B | $372.2M | ||
| Q3 25 | $3.2B | $376.7M | ||
| Q2 25 | $2.3B | $580.5M | ||
| Q1 25 | $2.3B | $583.4M | ||
| Q4 24 | $2.4B | $585.3M | ||
| Q3 24 | $618.7M | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $3.5B | $693.1M | ||
| Q3 25 | $5.2B | $727.2M | ||
| Q2 25 | $4.8B | $757.8M | ||
| Q1 25 | $3.7B | $798.5M | ||
| Q4 24 | $4.1B | $778.3M | ||
| Q3 24 | $2.9B | $749.6M | ||
| Q2 24 | $2.6B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $7.3B | $1.3B | ||
| Q3 25 | $9.2B | $1.3B | ||
| Q2 25 | $7.7B | $1.5B | ||
| Q1 25 | $6.4B | $1.6B | ||
| Q4 24 | $6.8B | $1.6B | ||
| Q3 24 | $3.6B | $1.5B | ||
| Q2 24 | $3.1B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 1.04× | 0.54× | ||
| Q3 25 | 0.63× | 0.52× | ||
| Q2 25 | 0.47× | 0.77× | ||
| Q1 25 | 0.62× | 0.73× | ||
| Q4 24 | 0.59× | 0.75× | ||
| Q3 24 | 0.22× | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-802.7M | — |
| Free Cash FlowOCF − Capex | $-1.2B | — |
| FCF MarginFCF / Revenue | -598.0% | — |
| Capex IntensityCapex / Revenue | 201.2% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-2.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-802.7M | $43.7M | ||
| Q3 25 | $-199.0M | $60.8M | ||
| Q2 25 | $-163.4M | $12.0M | ||
| Q1 25 | $-215.5M | $35.5M | ||
| Q4 24 | $-677.0M | $33.1M | ||
| Q3 24 | $-160.1M | $53.9M | ||
| Q2 24 | $-115.2M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-1.2B | $43.5M | ||
| Q3 25 | $-283.9M | $57.0M | ||
| Q2 25 | $-282.4M | $9.3M | ||
| Q1 25 | $-254.3M | $26.9M | ||
| Q4 24 | $-927.8M | $31.0M | ||
| Q3 24 | $-198.1M | $49.8M | ||
| Q2 24 | $-132.4M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -598.0% | 22.1% | ||
| Q3 25 | -112.5% | 31.7% | ||
| Q2 25 | -118.4% | 5.1% | ||
| Q1 25 | -118.9% | 15.9% | ||
| Q4 24 | -432.8% | 16.6% | ||
| Q3 24 | -150.5% | 29.6% | ||
| Q2 24 | -91.2% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 201.2% | 0.1% | ||
| Q3 25 | 33.6% | 2.2% | ||
| Q2 25 | 49.9% | 1.5% | ||
| Q1 25 | 18.2% | 5.1% | ||
| Q4 24 | 117.0% | 1.1% | ||
| Q3 24 | 28.9% | 2.4% | ||
| Q2 24 | 11.9% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -1.62× | 11.20× | ||
| Q2 25 | -0.20× | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | -1.28× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MARA
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
